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Advanced and intensive treatment of solid cancer and hema-
tologicalmalignancies is a success history inmodernmedicine.
However, the ﬂipside of treatment with ionization therapy,
chemotherapeutic and antineoplastic drugs, is among others,
risks for developing heart failure. Thus, treating a disease with
high mortality with a therapeutic regimen that gives the
patient another life-threatening disease is problematic.
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There is a wide spectrum of anticancer drugs with a
correspondingly wide spectrum of side effects. This includes
a direct cardiotoxic effect with reversible or irreversible
myocyte injury, which may result in temporary or permanent
left ventricular (LV) systolic dysfunction. In addition,
ischemia, arrhythmia, pericarditis, endomyocardial ﬁbrosis,
and hyper- and hypotension represent possible side effects
and therefore also targets for treatment (1).
The incidence of cardiovascular side effects of modern
cancer therapy is not well deﬁned and varies among different
agents. Anthracyclines, “the meanest boy in class,” induces
irreversible myocardial damage, and the cardiotoxicity is
dose-dependent and cumulative and can appear many years
after exposition. Heart failure may appear in up to half of
the patients receiving high doses (2) but may be as low as 3%
for those receiving low doses (3). Newer agents like trastu-
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the contents of this paper to disclose.loss (4). The risk of heart failure during treatment with tra-
stuzumab as adjuvant therapy is approximately 5% but may be
as high as 26% in combination with anthracyclines (5,6).
Presently, there is limited evidence regarding management
of cardiovascular side effects during and after cancer therapy,
and current practice is based largely on expert opinion (7).
However, the best strategy for treatment and prevention
of further deterioration of chemotherapy-induced cardio-
myopathy is withdrawal or use of fewer cardiotoxic agents.
This must always be balanced against the desire to cure the
malignant disease. A few studies suggest that treatment with
angiotensin-converting enzyme (ACE) inhibitors, angio-
tensin II receptor blockers, or beta-blockers as a single-drug
therapy may protect against chemotherapy-induced cardio-
myopathy (8,9). Interestingly, it has been proposed that
carvedilol may exert its effect in part through a potent anti-
oxidant effect, which could mean that it targets one of the
mechanisms of anthracycline-induced cardiomyopathy (10).
In their paper in this issue of the Journal, Bosch et al. (11)
report the ﬁrst results from a new prevention strategy. The
OVERCOME (preventiOn of left Ventricular dysfunction
with Enalapril and caRvedilol in patients submitted to
intensive ChemOtherapy for the treatment of Malignant
hEmopathies) trial combined an ACE inhibitor (enalapril)
with a beta-blocker (carvedilol) and was able to demonstrate
that this regimen could prevent a reduction in LV ejection
fraction in patients treated with intensive chemotherapy.
They also report that the combined therapy was well toler-
ated and safe. The OVERCOME trial is the ﬁrst cardiac
failure prevention study in oncology to use both cardiac
magnetic resonance (CMR) and echocardiography to assess
LV function. The authors included 90 patients, 45 in the
control group and 45 in the active treatment group. They
were, however, only able to perform follow-up CMR
studies of 59 patients, and differences between treated and
control subjects were only marginally signiﬁcant. The
follow-up echocardiographic study included 79 patients and
showed a signiﬁcant beneﬁt from treatment by enalapril and
carvedilol. This result is in line with other relatively small
studies that show positive effects on LV function by ACE
inhibitor and beta-blocker therapy. The main effects in this
trial originated from patients treated for leukemia, and the
effect was neutral for patients treated for Hodgkin and non-
Hodgkin lymphoma and multiple myeloma. Furthermore,
the study did not compare combined therapy to therapy with
beta-blocker or with ACE inhibition alone, and the study
was not blinded. This study design leaves many questions
that need answers. The paper does not detail the oncological
treatment regimens, causes of deaths are not stated, and
possible mechanisms of the positive effects on cardiac func-
tion can only be speculations.
As advised in current guidelines, treatment of chemo-
therapy-induced heart failure should follow the same prin-
ciple as in treating other cardiomyopathies (12). The
rationale is that treatment with beta-blockers and ACE-
inhibitors reduces the adrenergic response and prevents
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2364remodeling in a failing heart (13,14). One can always discuss
whether this principle is valid independently of the reason
for the heart failure, and further studies should be per-
formed, focused on patients with chemotherapy-induced
heart failure. The current main strategy is to stop ongoing
chemotherapy and to avoid further use of anthracyclines
along with traditional heart failure therapy. There are still
some main questions that need further exploration. How
much deterioration of the ventricle is acceptable before
restart of chemotherapy? Which drug is the best for treating
the heart failure, and is the combination as used in the study
by Bosch et al. (11) even better? Is it possible to prevent
heart failure during extensive therapy for malignant disease
by using conventional heart failure therapy? And the more
ethical question is: how much heart failure is acceptable as
a prize for the cure of a malignant disease? The time has now
come to answer these important questions in large multi-
center trials. The means to detect ventricular function in the
present OVERCOME trial was to some degree inadequate.
Future trials should therefore include assessment of LV
function by strain imaging, which represents a more sensi-
tive method than ejection fraction with which to detect early
and pre-clinical signs of LV dysfunction (15). Furthermore,
assessment of diastolic function may represent a means to
identify patients who may be sensitive to chemotherapeutic
cardiotoxicity because they have a ﬁlling problem, which
may be aggravated if systolic function deteriorates. Because
hypertension, even when mild, may represent a signiﬁcant
stress to myocardium with impaired function, it should be
determined whether lowering of blood pressure to normal
values may reduce the deleterious effects of chemotherapy on
cardiac function.
It is striking that it has taken more than 15 years from the
extensive documentation that the combination of ACE
inhibition and beta-blocker can markedly reduce mortality in
the general heart failure population to testing of this strategy
during cancer therapy. This indicates the need for better and
faster transfer of knowledge between cardiology and
oncology, and the recently developed “specialty” cardio-
oncologist is a step in the right direction.
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